Kungshusen Medicinska has been acquired by Diploma
Kungshusen Medicinska AB has been acquired by Diploma PLC. Through the acquisition, Diploma gains access to a unique platform for the distribution of medtech products in Sweden.
Founded in 1977, Kungshusen is a leading Swedish distributor of medtech products in endoscopy and diathermy. The company has established a solid supplier network comprising leading international manufacturers of high-quality products and has built a strong reputation in the market based on its one-stop shop offering, high deliverability and vast sector experience. Headquartered in Mariefred, Kungshusen serves healthcare providers in all major regions of Sweden. Kungshusen’s revenues amount to approximately US$14 million.
Diploma is a UK-listed international group supplying specialized products and services within seals, controls and life sciences. Within the life sciences segment, the company supplies clinical diagnostics instruments and surgical medical devices to hospitals, clinics and laboratories, primarily in Canada, Europe and Australia. Diploma’s revenues amount to approximately US$740 million.
Oaklins’ Swedish team was engaged to run a structured sale process and advised the seller throughout the transaction.
Henrik Svärdskog
CEO and Co-owner, Kungshusen Medicinska AB
Prata med transaktionsteamet
Relaterade transaktioner
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer